Twitxy Saved

Hemab Therapeutics

Verified account This account is verified. Learn more

@Hemab_Tx

We're pioneering the first targeted preventative treatments and functional cures for underserved bleeding and thrombotic disorders.
hemab.com Joined July 2021
40 Following 199 Followers 300 Posts

Latest posts 5

Hemab Therapeutics Verified account @Hemab_Tx
Some bleeding disorders remain overlooked. That doesn’t make their impact any smaller.

For people living with Glanzmann thrombasthenia, Von Willebrand disease, or Factor VII deficiency, managing bleeding can bring complexity, uncertainty, and challenges that extend outside the hospital.

Patients, families, advocates, nurses, clinicians, and researchers each bring an essential perspective to progress.

At Hemab, our focus is clear: urgently advance treatments for serious and overlooked coagulation disorders.

Share your journey with us at hemab.typeform.com/contact
0:07
Hemab Therapeutics Verified account @Hemab_Tx
Every person living with a platelet disorder has a story worth hearing.

On Sport Purple for Platelets Day, we stand with the platelet-disorders community to raise awareness and recognition for people living with these conditions.

For people living with Glanzmann thrombasthenia (GT), an inherited platelet function disorder, bleeding can be a frequent and ongoing part of daily life. In the GT360 study, 88% of respondents reported at least one bleed in the previous week, highlighting the significant burden on patients and families.

Awareness is a starting point. Meaningful progress requires continued attention, research, and innovation.

At Hemab, we are committed to advancing therapies for coagulation disorders and helping drive better outcomes for lived experience experts, families, and the broader bleeding disorders community.
Hemab Therapeutics Verified account @Hemab_Tx
For far too long, people living with underserved bleeding disorders have been told to make do with treatments that weren't built for them and changing that takes more than great science, it takes strong leadership at every level, including the boardroom. That's why we're excited to welcome Keli Walbert to Hemab's Board of Directors.

Keli brings nearly two decades of commercial leadership in rare disease, most recently as EVP, U.S. Commercial at Horizon Therapeutics, where she helped scale the company's rare disease portfolio from roughly $300M to nearly $4B in annual sales, including the launch of TEPEZZA and the relaunch of UPLIZNA, ahead of Horizon's $28B acquisition by Amgen. Earlier, she held leadership roles at AbbVie, Abbott, and UnitedHealthcare. She currently serves on the board of Spruce Biosciences and previously served on the board of Apellis Pharmaceuticals through its acquisition earlier this year.

As we work to bring long-overdue treatments to this overlooked community, Keli's experience strengthens the leadership guiding us there.

Read more: ir.hemab.com/news-releases/…
0:05
Hemab Therapeutics Verified account @Hemab_Tx
Advancing underserved bleeding disorder research takes collaboration.

Hemab is currently enrolling participants for a Phase 2b clinical trial evaluating sutacimig, an investigational therapy designed to increase Factor VII levels and support the body's ability to form clots in people living with Factor VII deficiency (FVIID).

Learn more about the FVIID study: clinicaltrials.gov/study/NCT07347…

Questions? Contact us at hemab.typeform.com/contact

Note: This post contains forward-looking statements subject to important risks and uncertainties. See our SEC filings for more detail:
ir.hemab.com/sec-filings/se…
Hemab Therapeutics Verified account @Hemab_Tx
We're proud to announce that the first healthy volunteer has been dosed in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy menstrual bleeding.

Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, yet too many are told what they’re experiencing is “normal,” leading to delayed diagnosis, disrupted daily life, and under-treated symptoms.

HMB-003 is a novel fatty-acid-conjugated peptide antifibrinolytic, designed to stabilize clots and reduce bleeding. It directly inhibits plasmin at its active site, blocking fibrinolysis independently of the plasminogen activation pathway.

If you’d like to get updates on this program, please sign up here to talk to our advocacy team: hemab.typeform.com/contact

Read more at ir.hemab.com/news-releases/…
0:10